Product candidate
Discovery
In vivo PoC
Phase 1
Phase 2
Phase 3 / pivotal
Milestones
Cancer gene therapy
circVec
circRNA vector
circRNA vector
Vaccines
Rare disease
Mutant KRAS1
Pancreatic cancer & Multiple Myeloma
TG01/QS-21 +/- anti-PD-1
Cancer Indication:
Cancer gene therapy
Product candidate: circVec circRNA vector
Next expected event: 2H 2023
In vivo proof-of-concept data
Product candidate: circVec circRNA vector
Next expected event: 2H 2023
In vivo proof-of-concept data
Discovery
In vivo PoC
Phase 1
Phase 2
Phase 3 / pivotal
Cancer Indication:
Vaccines Product candidate: circVec circRNA vector
Next expected event: 2H 2023
In vivo proof-of-concept data
Next expected event: 2H 2023
In vivo proof-of-concept data
Discovery
In vivo PoC
Phase 1
Phase 2
Phase 3 / pivotal
Cancer Indication:
Rare disease
Product candidate: circVec circRNA vector
Next expected event: 2H 2023
In vivo proof-of-concept data
Product candidate: circVec circRNA vector
Next expected event: 2H 2023
In vivo proof-of-concept data
Discovery
In vivo PoC
Phase 1
Phase 2
Phase 3 / pivotal
Cancer Indication:
Pancreatic cancer & Multiple Myeloma
Combination with: TG01/QS-21 +/- anti-PD-1
Product candidate: Mutant KRAS1
Next expected event: 1H 2024
Safety and immune response data
Combination with: TG01/QS-21 +/- anti-PD-1
Product candidate: Mutant KRAS1
Next expected event: 1H 2024
Safety and immune response data
Discovery
In vivo PoC
Phase 1
Phase 2
Phase 3 / pivotal
Two trials run and financed by collaboration partners
1Pending additional financing or partnership